TOP TEN perturbations for 1022_f_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1022_f_at
Selected probe(set): 208259_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1022_f_at (208259_x_at) across 6673 perturbations tested by GENEVESTIGATOR:
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):9.399811Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):9.3988Number of Samples:4 / 8
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (CpG A) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):7.5843124Number of Samples:7 / 8
Experimental | dendritic cell study 6 (CpG A) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):6.0307426Number of Samples:4 / 4
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (CpG A; RN486) / dendritic cell study 6 (CpG A)
Relative Expression (log2-ratio):-4.216255Number of Samples:4 / 7
Experimental | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (CpG A) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (CpG A; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):3.3680573Number of Samples:4 / 8
Experimental | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-1.931694Number of Samples:2 / 3
Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-1.2338028Number of Samples:2 / 3
Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):-1.1943169Number of Samples:2 / 4
Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
Control | non-tumor cortical tissue |
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-1.1593099Number of Samples:3 / 3
Experimental | glioma study 17 (glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |